Latest Healthcare News

Vitura Health has appointed Justin James as its new CEO, bringing a wealth of healthcare leadership and a proven track record in specialty therapies to accelerate the company’s transformation.

Wellnex Life has extended its licensing and supply agreement with Haleon UK for soft gel liquid paracetamol products until March 2027, reinforcing its position in the global analgesics market.

Emyria Limited has launched a targeted recruitment campaign in New South Wales to establish its fourth state-based clinical operation, aiming to tap into Australia's largest mental health market amid rising psychological injury claims.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

Little Green Pharma has issued a supplementary scheme booklet updating Cannatrek shareholders on the acquisition progress, including a revised timetable and the termination of a planned sale and leaseback of its WA production facility. Both companies’ boards continue to recommend the scheme, supported by an independent expert’s positive assessment.

AdAlta’s BZDS1901 CAR-T therapy shows remarkable tumour shrinkage and complete responses in advanced mesothelioma patients, doubling expected outcomes and paving the way for higher dosing and expanded trials.

AVITA Medical has lodged a new $200 million shelf registration with the SEC, renewing its capacity to issue various securities in the US market. While no immediate capital raising is planned, this move preserves the company’s financial agility for future growth opportunities.

Enlitic has landed a US$1.2 million contract to migrate and standardise millions of medical imaging records for Parkland Health, marking its third major US healthcare win this month.

Actinogen Medical has initiated the open-label extension of its XanaMIA Alzheimer’s trial, offering all participants active Xanamem treatment for up to 25 months to gather long-term safety and efficacy data ahead of final trial results.

Bioxyne Ltd has secured a manufacturing agreement with global cannabis giant Aurora Cannabis, marking a major step in its international expansion of pharmaceutical-grade medicinal cannabis products.

Pro Medicus Limited has announced an on-market buy-back program targeting up to 10% of its ordinary shares, aiming to return capital to shareholders without requiring approval.

Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.